Asset Details
Do you wish to reserve the book?
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?
Do you wish to request the book?
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antisense oligonucleotide-directed liver therapy: a new tool in the MASH armamentarium?
2025
Overview
MASLD is characterised by fat accumulation within hepatocytes and requires the coexistence of at least one cardiometabolic risk factor. 1 The natural history and pathophysiological perturbations underpinning the development and progression of MASLD are evolving, 2 with increasingly targeted precision therapies being developed. A key secondary endpoint was the relative change in hepatic steatosis from baseline by MRI-derived proton density fat fraction (MRI-PDFF). In particular, the small sample size did not allow for adequate powering for registrational endpoints, although the effect size was large enough to meet statistical significance.
Publisher
Elsevier Ltd,Elsevier Limited
We currently cannot retrieve any items related to this title. Kindly check back at a later time.